Call Options

25 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$212.22 - $292.96 $22.5 Million - $31 Million
-105,800 Reduced 31.32%
232,000 $49.2 Million
Q2 2024

Aug 15, 2024

SELL
$193.33 - $291.99 $17.9 Million - $27.1 Million
-92,700 Reduced 21.53%
337,800 $94.6 Million
Q1 2024

May 07, 2024

BUY
$171.37 - $283.23 $33.5 Million - $55.3 Million
195,400 Added 83.11%
430,500 $115 Million
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $16.4 Million - $32.2 Million
-135,900 Reduced 36.63%
235,100 $54.4 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $686,388 - $1.06 Million
-4,700 Reduced 1.25%
371,000 $54.2 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $25.4 Million - $38.8 Million
124,400 Added 49.5%
375,700 $86.8 Million
Q1 2023

May 16, 2023

BUY
$231.06 - $307.08 $6.77 Million - $9 Million
29,300 Added 13.2%
251,300 $60.9 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $10.9 Million - $55.2 Million
186,000 Added 516.67%
222,000 $64.4 Million
Q3 2022

Nov 14, 2022

SELL
$60.57 - $79.51 $1.13 Million - $1.49 Million
-18,700 Reduced 34.19%
36,000 $2.34 Million
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $2.17 Million - $3.75 Million
37,400 Added 216.18%
54,700 $3.92 Million
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $838,350 - $1.53 Million
-15,000 Reduced 46.44%
17,300 $1.7 Million
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $484,678 - $637,103
6,700 Added 26.17%
32,300 $2.74 Million
Q3 2021

Nov 15, 2021

BUY
$78.35 - $105.02 $1.31 Million - $1.75 Million
16,700 Added 187.64%
25,600 $2.04 Million
Q2 2021

Aug 11, 2021

BUY
$97.2 - $137.59 $87,480 - $123,831
900 Added 11.25%
8,900 $867,000
Q1 2021

May 17, 2021

BUY
$108.54 - $125.2 $65,124 - $75,120
600 Added 8.11%
8,000 $936,000
Q4 2020

Feb 16, 2021

SELL
$110.06 - $133.7 $1.8 Million - $2.19 Million
-16,400 Reduced 68.91%
7,400 $823,000
Q3 2020

Nov 16, 2020

SELL
$99.78 - $124.21 $1.81 Million - $2.25 Million
-18,100 Reduced 43.2%
23,800 $2.83 Million
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $2.16 Million - $4.53 Million
36,000 Added 610.17%
41,900 $4.75 Million
Q1 2020

May 15, 2020

SELL
$66.76 - $93.49 $647,572 - $906,853
-9,700 Reduced 62.18%
5,900 $394,000
Q3 2019

Nov 14, 2019

SELL
$84.4 - $106.53 $2.84 Million - $3.58 Million
-33,600 Reduced 68.29%
15,600 $1.35 Million
Q2 2019

Aug 14, 2019

SELL
$91.13 - $142.5 $7.69 Million - $12 Million
-84,400 Reduced 63.17%
49,200 $5.16 Million
Q1 2019

May 15, 2019

SELL
$103.48 - $143.84 $4.85 Million - $6.75 Million
-46,900 Reduced 25.98%
133,600 $16.7 Million
Q4 2018

Feb 14, 2019

BUY
$94.77 - $215.54 $1.16 Million - $2.63 Million
12,200 Added 7.25%
180,500 $20.3 Million
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $8.6 Million - $12.5 Million
41,500 Added 32.73%
168,300 $36 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $12.9 Million - $39.8 Million
126,800 New
126,800 $35.5 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.